Enanta Pharmaceuticals reported $-11428000 in EBITDA for its fourth fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Abbvie ABBV:US $ 6447M 311M
Acorda Therapeutics ACOR:US $ -18.65M 8.53M
Amgen AMGN:US $ 2970M 89M
Anika Therapeutics ANIK:US $ 2.52M 5.09M
Arrowhead Research ARWR:US $ -26310000 4.1M
AstraZeneca AZN:LN 2149M 322M
Biogen BIIB:US $ 1147.6M 41.7M
Bristol Myers Squibb BMY:US $ 5679M 455M
Gilead Sciences GILD:US $ 2816M 669M
GlaxoSmithKline GSK:LN 2626M 584M
Halozyme Therapeutics HALO:US $ 51.47M 26.95M
Insmed INSM:US $ -79912000 10.78M
Johnson & Johnson JNJ:US $ 8103M 786M
Karyopharm Therapeutics KPTI:US $ -52138000 15.33M
Neurocrine Biosciences NBIX:US $ 34M 40M
Novartis NOVN:VX SF 4349M 79M
Novavax NVAX:US $ -206.32M 25.26M
Pfizer PFE:US $ 7593M 610M
Sarepta Therapeutics SRPT:US $ -132.94M 30.49M
YTE INCY:US $ 120.19M 73.23M